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Introduction
Asthma is a chronic inflammatory disease 
of the airways that is characterized by 
increased airway responsiveness to multiple 
stimuli. It is considered to be the most 
common chronic condition encountered in 
pregnancy.1 The prevalence of asthma during 
pregnancy in Europe has been estimated to 
be between 4% and 8%.2 Asthma-related 
morbidity and mortality rates during 
pregnancy are comparable to those in the 
general population. Mortality from asthma 
in the United States is calculated to be 
2.1 persons per 100,000 population.1 No 
local or European data has been identified 
in the literature regarding mortality. Many 
physiological and anatomical changes of 
pregnancy affect the respiratory system. 
These changes often affect the presentation 
and management of the various respiratory 
illnesses in pregnancy, including asthma,3 
and asthma and its treatment can affect 
pregnancy outcomes.4 Pregnancy can have a 
variable impact on asthma, and there is no 
general rule to predict in whom it is going 
to be better, stable or worse.5 The National 
Asthma Education and Prevention Program 
(NAEPP) “Working Group Report on Managing 
Asthma During Pregnancy: Recommendations 
for Pharmacologic Treatment—Update 2004” 
emphasizes that maintaining adequate 
control of asthma during pregnancy is 
important for the health and well-being of 
both the mother and her baby.6
Differential Diagnosis
A number of conditions that can mimic 
symptoms of asthma in pregnant patients 
include the following:
•	 Amniotic fluid embolism1 
Amniotic fluid embolism is a rare 
event which is precipitated when 
amniotic fluid is able to breach the 
physical barrier between the maternal 
and foetal environments as a result of 
uterine trauma. It can take a variety 
of clinical presentations but a classical 
presenting sign is dyspnoea, which in 
the acute situation can mimic an acute 
exacerbation of asthma, particularly in 
patients who are known to suffer from 
asthma.7 
•	 Acute congestive heart failure, 
secondary to peripartum 
cardiomyopathy1
Peripartum cardiomyopathy is an 
uncommon disorder associated with 
pregnancy in which the heart dilates 
and weakens, leading to symptoms of 
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Abstract
Asthma is the most common chronic condition encountered in 
pregnancy. Due to lack of evidence on the adverse effects of asthma 
medication during pregnancy, there is persistent concern regarding use 
of asthma-related medication throughout the pregnancy, management 
of exacerbations and asthma management during labour.  Several 
respiratory-related physiological changes are said to occur during 
pregnancy which could possibly worsen or improve asthma, and asthma 
as well as its treatment can affect pregnancy outcomes. The aim of this 
paper is to summarize current literature findings on clinical management 
issues encountered in this cohort of patients. 
Pregnancy and asthma
Educational aims
•	 To provide information on the management of asthma during pregnancy
•	 To emphasize that benefits of asthma medication outweigh the risks 
•	 To highlight the importance of a multidisciplinary approach in the care 
of a pregnant asthmatic 
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heart failure. This condition may be 
difficult to diagnose because symptoms 
of heart failure can mimic those of 
pregnancy as well as other respiratory 
conditions such as asthma.8 
•	 Physiologic dyspnoea of pregnancy1 
Dyspnoea is commonly reported by 70% 
of healthy pregnant women during their 
daily living activities, starting from the 
very first trimester of gestation. Possible 
explanations could be an increased 
awareness of the new sensation of 
the physiological hyperventilation 
associated with pregnancy or an 
increased central perception of 
respiratory discomfort or a combination 
of these two. This should be a diagnosis 
of exclusion after pulmonary and cardiac 
causes for the dyspnoea have been 
excluded.9
Pathophysiology
Asthma control often changes during 
pregnancy; in approximately one-third of 
women asthma symptoms worsen, in one-
third they improve, and in the remaining 
one-third they remain unchanged.10 
Pregnancy has a significant effect on the 
respiratory physiology of a woman. While the 
respiratory rate and vital capacity does not 
change in pregnancy, tidal volume, minute 
ventilation (40%), and minute oxygen 
uptake (20%) increase, with a resultant 
decrease in functional residual capacity and 
residual volume of air as a consequence 
of the elevated diaphragm. In addition, 
airway conductance is increased and total 
pulmonary resistance is reduced, possibly as 
a result of the influence of progesterone. The 
consequence of these physiologic changes is 
a hyperventilatory picture as a normal state 
of affairs in the later half of pregnancy. This 
results in the picture of a chronic respiratory 
alkalosis during pregnancy, with a decreased 
partial pressure of carbon dioxide (pCO2), 
decreased bicarbonate, and increased pH. A 
normal pCO2 in a pregnant patient may signal 
impending respiratory failure. The increased 
minute ventilation and improved pulmonary 
function in pregnancy promote more efficient 
gas exchange from the maternal lungs to 
the blood. Therefore, changes in respiratory 
status occur more rapidly in pregnant 
patients than in non-pregnant patients.1
Non-pharmacological management
Non-pregnant asthmatics
Asthmatic patients should be strongly 
advised to quit smoking and smoking 
cessation advice given as necessary.  Weight 
loss in overweight patients has many health 
benefits, and should be supported in people 
with asthma since, if successful, it may 
lead to improvements in asthma symptoms. 
Allergen avoidance and elimination of 
exposure to trigger factors is of optimal 
importance. The practitioner must also 
ensure that the patient is adherent with 
existing therapies. Inhaler technique should 
also be checked and explained as necessary. 
The use of a spacer should be strongly 
encouraged. 
Pregnant asthmatics
Non-pharmacological management is 
very similar to non-pregnant patients. 
Pharmacologic as well as cognitive 
interventions should be offered to pregnant 
women to assist in smoking cessation, in 
view of the known risks associated with 
cigarette smoking.3 Avoidance of exposure 
to allergens as well as any situation which 
could potentially trigger asthma symptoms 
should be avoided.  The importance of a 
good inhaler technique and spacer use 
should be emphasized.
Pharmacological management
Non-pregnant asthmatics
Before initiating asthma medication, 
practitioners should address non-
pharmacological measures. A short acting 
β2-agonists (SABA) is recommended for 
symptom relief, on an as needed basis, 
in the mildest cases of asthma. Inhaled 
corticosteroids (ICS) are the recommended 
preventer drug for adults for achieving 
overall treatment goals. If asthma symptoms 
remain uncontrolled, add-on therapy to 
ICS in adults is an inhaled long-acting 
β2- agonist (LABA), which should be 
considered before going above a dose of 400 
micrograms beclomethasone or equivalent 
per day and certainly before going above 
800 micrograms. If asthma control remains 
suboptimal after the addition of LABA, then 
the dose of ICS should be increased to 800 
micrograms/day, if not already on these 
doses. A leukotriene receptor antagonist 
should also be considered at any stage after 
initiation of an ICS. Theophyllines might also 
be considered at times.4
Pregnant asthmatics 
There is much concern amongst pregnant 
asthmatic patients regarding the use of 
their asthma medications. In fact lack 
of adherence to therapy is a frequent 
occurrence, because such patients are 
worried about medication effects on the 
foetus.1 Current available literature shows 
that the management of asthma remains 
largely unchanged compared to the non-
pregnant state.3 Differences were found in 
the prevalence of prescribing of asthma 
medications during and surrounding 
pregnancy in Europe from data recorded in 
seven European population-based databases. 
Inhaled β2-agonists and ICS were, however, 
the most popular therapeutic regimens in all 
databases.2
According to the BTS guidelines, the 
following drugs should be used as normal 
during pregnancy: SABA, LABA, ICS, oral 
and intravenous theophyllines. They also 
recommend that systemic corticosteroids 
should also be used as normal when 
indicated during pregnancy for severe 
asthma. If leukotriene receptor antagonists 
are required to achieve adequate control of 
asthma then they should not be withheld 
during pregnancy.4 ICS prevent exacerbations 
of asthma during pregnancy, and their 
cessation during pregnancy is a significant 
risk factor for exacerbations.10 ICS are the 
preferred treatment for long-term control 
medication. Budesonide is the preferred 
ICS because more data is available on 
using budesonide in pregnant women than 
is available on other ICS, and the data is 
reassuring. However, no data indicates that 
the other ICS preparations are unsafe during 
pregnancy. Garne et al also concluded that 
the use of ICS during the first trimester of 
pregnancy seems to be safe in relation to the 
risk for a range of specific major congenital 
anomalies.11 It has also been recommended 
that a low priority should be placed on 
stepping down treatment (however guided) 
until after delivery.10 There is minimal 
published data on the use of leukotriene 
receptor antagonists during pregnancy; 
however, animal safety data submitted to 
the Food and Drug Administration (FDA) is 
reassuring.6 Treatment to control symptoms 
and hence minimize adverse outcomes 
from exacerbations using recommended 
asthma medications is considered of utmost 
importance. 
Acute exacerbations
During pregnancy, exacerbations of asthma 
which require medical intervention occur in 
about 20% of women, with approximately 
6% of women requiring hospitalization. 
Severe asthma appears to be the biggest risk 
factor for exacerbations during pregnancy 
Issue 22  2016 Journal of the Malta College of Pharmacy Practice          33
although some have noted that respiratory 
viral infections are also a common cause. 
Pregnant women appear also to be 
particularly susceptible to the effects of viral 
respiratory infections, including influenza.10 
This could be explained by the changes in 
cell-mediated immunity during pregnancy 
which may lead to exacerbations of asthma.12 
Non-adherence to asthma treatment could 
also be an important cause. It is safer for 
pregnant women who have asthma to be 
treated with asthma medications than to 
have asthma symptoms and exacerbations. 
Monitoring and making appropriate 
adjustments in therapy may be required to 
maintain lung function and, hence, blood 
oxygenation that ensures oxygen supply 
to the fetus.6 Exacerbations are common 
in pregnancy, particularly in the second 
trimester. Exacerbations and poor asthma 
control during pregnancy may be due to 
mechanical or hormonal changes, or to 
cessation or reduction of asthma medications 
due to concerns by the mother. Exacerbations 
and poor symptom control are associated 
with worse outcomes, as described below, for 
both the baby and the mother.10 
The British Thoracic Society (BTS) 
guidelines recommend that during an 
exacerbation, pregnant mothers should be 
administered drug therapy as for non-
pregnant patients.4 Acute severe asthma 
in pregnancy is an emergency situation 
and should be treated aggressively 
with nebulized SABA, oxygen and early 
administration of systemic corticosteroids.10 
Asthma exacerbation during pregnancy is not 
associated with adverse pregnancy outcomes 
while managed appropriately with systemic 
corticosteroids.13 Magnesium sulphate 
can also be administered if necessary. 
Delivery of high flow oxygen immediately to 
maintain oxygen saturations of 94 to 98% 
is recommended together with continuous 
foetal monitoring,4 so as to avoid foetal 
hypoxia. Respiratory infections should be 
monitored and managed appropriately during 
pregnancy.10 Infectious respiratory illness, 
including pneumonia and tuberculosis, 
are similarly managed in pregnancy with 
antibiotics, although special attention may 
be needed for antibiotic choices with more 
pregnancy safety data.3
When mechanical ventilation is 
necessary, consideration should be given to 
the maternal haemodynamics of pregnancy 
and foetal oxygenation. Maintaining 
maternal oxygen saturation above 95% is 
recommended to sustain optimal foetal 
oxygenation.3
It is also recommended that there should 
be close liaison between the respiratory 
physician and obstetrician, with early 
referral to critical care physicians for women 
with acute severe asthma.4 Prevention of 
exacerbations is essential to reduce the risk 
of complications and poor outcome.14 
Management during labour
During labour and delivery, usual controller 
medications should be taken, with a SABA, 
such as salbutamol, if needed.10 Acute 
exacerbations during labour and delivery are 
uncommon,4 but bronchoconstriction may be 
induced by hyperventilation during labour, 
and should be managed with SABA. Neonatal 
hypoglycemia may be seen, especially in 
preterm babies, when high doses of beta2-
agonists have been given within the last 48 
hours prior to delivery. If high doses of SABA 
have been given during labour and delivery, 
blood glucose levels should be monitored in 
the baby (especially if preterm) for the first 
24 hours.10
If anaesthesia is required, regional 
blockade is preferable to general 
anaesthesia. In the absence of an acute 
severe asthma attack, caesarean section 
should be reserved for the usual obstetric 
indications. Prostaglandin F2α should be 
used with caution because of the risk of 
inducing bronchoconstriction.4 
Women receiving steroid tablets at a 
dose exceeding prednisolone 7.5 mg per 
day for more than 2 weeks prior to delivery 
should receive parenteral hydrocortisone 
100 mg 6–8 hourly during labour.4 
Monitoring 
Pregnancy profoundly affects asthma-
related health care use.13 It is 
recommended that pregnant asthmatics 
should be monitored closely, particularly 
those patients with moderate or severe 
asthma to keep their asthma well 
controlled.4 Monthly evaluations of asthma 
history and pulmonary function (spirometry 
is preferred, but measurement with a peak 
flow meter is generally sufficient) are 
recommended.6 Regular evaluation will 
allow the opportunity to step-up treatment 
as necessary.
Outcomes and complications 
Although women with mild asthma are 
unlikely to have problems, patients with 
severe asthma are at greater risk of 
deterioration. The deterioration risk is 
highest in the last portion of a pregnancy. 
In fact, severe and/or poorly controlled 
asthma has been associated with numerous 
adverse perinatal outcomes as per Table 
1.1,5,6,14,15 
This risk of giving birth to a small 
or preterm infant appears to be small 
and may be minimized by good control 
of asthma. Studies have indicated that 
low-birth-weight infants are more common 
in women with daily symptoms or low 
expiratory flow than in women without 
asthma.1
Table 1: Adverse perinatal outcomes 
that have been associated with 
uncontrolled asthma during pregnancy
Adverse perinatal outcomes
Pre-eclampsia 
Pregnancy-induced hypertension 
Uterine haemorrhage 
Preterm labour 
Premature birth 
Congenital anomalies 
Intra-uterine growth restriction 
Low birth weight 
Breech presentation
Neonatal hypoglycemia
Neonatal seizures
Table 2: Adverse maternal outcomes have been associated with  
uncontrolled asthma during pregnancy
Adverse outcomes in pregnant asthmatics
Respiratory failure  +/- mechanical ventilation 
Barotrauma 
Complications of systemic corticosteroid use 
Mortality 
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Asthma can also lead to complications 
in pregnant women as per table 2.1 
According to Blais et al, only 
severe asthma exacerbations were 
found to significantly increase the risk 
of congenital malformations in this 
representative study.16 However, it is 
uncertain whether this risk is associated 
with the exacerbation itself or the 
treatment given.2 Being able to identify 
complications associated with asthma 
during pregnancy is of great importance 
in providing appropriate asthma 
management and medical care to these 
pregnant women, which may have lifelong 
consequences for their offspring.15 Hence 
the importance of advising adherence 
with asthma medications, with the aim 
of achieving the best asthma control 
possible. 
Breastfeeding
Asthmatic women should be encouraged 
to breastfeed. Asthma medications should 
be taken as normal during lactation.4 
General advice
•	 Women should be advised about the 
importance of maintaining good control 
of their asthma during pregnancy to 
avoid problems for both mother and 
baby.
•	 Pregnant asthmatics should be advised 
that poorly controlled asthma, and 
exacerbations, provide a much greater 
risk to their baby than do asthma 
medication. 
•	 Smokers should be advised about the 
dangers for themselves and their babies 
and should be given appropriate smoking 
cessation advice. 
•	 Table 3 highlights a list of recommended 
interventions by health care professionals 
to pregnant asthmatics. 
Conclusion
The management of asthma during 
pregnancy remains mainly unchanged 
compared to a non-pregnant patient. The 
advantages of achieving asthma control 
and avoiding exacerbations appear to 
outweigh the potential risks related to 
asthma medication. Stepping down of 
treatment during pregnancy should be 
reserved for the post-partum period. In case 
of an exacerbation, this should be treated 
aggressively. 
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Table 3: Recommended interventions by health care  
professionals to pregnant asthmatics
Dispel any fears/misconceptions about use of asthma medication
Emphasize the importance of adherence to therapy
Highlight the risk of non-adherence to therapy for mother and foetus
Arrange regular follow-ups to identify symptoms of uncontrolled asthma 
Monitor inhaler technique
Emphasize the importance of using a spacer
Advise smoking cessation as necessary
Offer smoking cessation techniques as necessary
Provide the patient with an asthma self-management plan
Key points
•	 The management of asthma during pregnancy remains largely unchanged compared  
to a non-pregnant patient
•	 For both the mother and baby, the advantages of achieving asthma control and 
avoiding exacerbations appear to outweigh the potential risks related to asthma 
medication
•	 Stepping down of treatment should be reserved for the post-partum period. 
•	 In the case of an asthma exacerbation during pregnancy, this should be treated 
aggressively
•	 Pregnant women should be advised that an acute asthma attack is rare in labour but if 
this occurs, they should continue their usual asthma medications throughout labour
